Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Receivables (2016 - 2026)

Ani Pharmaceuticals' Receivables history spans 14 years, with the latest figure at $281.1 million for Q4 2025.

  • On a quarterly basis, Receivables rose 26.77% to $281.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $281.1 million, a 26.77% increase, with the full-year FY2025 number at $281.1 million, up 26.77% from a year prior.
  • Receivables hit $281.1 million in Q4 2025 for Ani Pharmaceuticals, up from $252.6 million in the prior quarter.
  • Over the last five years, Receivables for ANIP hit a ceiling of $281.1 million in Q4 2025 and a floor of $91.9 million in Q1 2021.
  • Historically, Receivables has averaged $171.9 million across 5 years, with a median of $171.4 million in 2022.
  • Biggest five-year swings in Receivables: surged 62.35% in 2022 and later dropped 4.9% in 2023.
  • Tracing ANIP's Receivables over 5 years: stood at $128.5 million in 2021, then surged by 32.61% to $170.4 million in 2022, then fell by 4.9% to $162.1 million in 2023, then soared by 36.8% to $221.7 million in 2024, then increased by 26.77% to $281.1 million in 2025.
  • Business Quant data shows Receivables for ANIP at $281.1 million in Q4 2025, $252.6 million in Q3 2025, and $225.7 million in Q2 2025.